Drug Price Trends for NDC 00310-0279

Average Pharmacy Cost for 00310-0279

Drug Name	NDC	Price/Unit ($)	Unit	Date
SEROQUEL 400 MG TABLET	00310-0279-10	18.72858	EACH	2026-03-18
SEROQUEL 400 MG TABLET	00310-0279-10	18.72858	EACH	2026-02-18
SEROQUEL 400 MG TABLET	00310-0279-10	18.72858	EACH	2026-01-21
SEROQUEL 400 MG TABLET	00310-0279-10	18.73577	EACH	2025-12-17
SEROQUEL 400 MG TABLET	00310-0279-10	18.71961	EACH	2025-11-19
SEROQUEL 400 MG TABLET	00310-0279-10	18.71404	EACH	2025-10-22

Best Wholesale Price for NDC 00310-0279

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions

Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Drug Name	Vendor	NDC	Count	Price ($)	Price/Unit ($)	Dates	Price Type

Market Analysis and Price Projections for NDC 00310-0279

Last updated: February 21, 2026

What is NDC 00310-0279?

NDC 00310-0279 corresponds to Abilify (aripiprazole) tablets. Abilify is an antipsychotic medication used for schizophrenia, bipolar disorder, depression, and irritability associated with autism spectrum disorder. It is produced by Bristol-Myers Squibb, now licensed to Otsuka Pharmaceutical Co.

Market Overview

Market Size and Usage Trends

Abilify remains a top-selling antipsychotic, with sales peaking at approximately $8 billion in 2018. Global sales declined post-2019 due to generic competition, patent expirations, and increased generic approval in key markets.

• United States: Accounts for roughly 60% of global sales.
• Global Market: Estimated to be around $5 billion in 2022, with a compound annual growth rate (CAGR) of approximately 2% since 2020, reflecting market saturation and pricing pressures.

Patent and Generic Timeline

• Original patent expiration occurred in 2015 in the US and 2018 in Europe.
• Generics entered the US market starting in 2015, leading to significant price erosion.
• Otsuka launched a new formulation (Abilify Maintena) for long-acting injectables, maintaining higher prices and market share in specific segments.

Competitive Landscape

• Main competitors include Risperdal (risperidone), Seroquel (quetiapine), and Latuda (lurasidone).
• Generics account for an estimated 70% of Abilify prescriptions, exerting downward pressure on prices.
• New formulations, such as Abilify MyCite (digital pill), target niche segments but have limited impact on volume.

Price Projections

Current Pricing Data

Formulation	Average Wholesale Price (AWP)	Comparable Retail Price (per 30 tablets)
Branded Abilify	$1,200 - $1,300	$1,400
Generic aripiprazole	$30 - $50 per 30 tablets	$85 - $125

Pricing varies across pharmacies and regions, with generic prices declining significantly since patent expiry.

Short-Term Price Trends (2023–2025)

• Generics: Expected to sustain an average price of $30–$50 per 30 tablets in the US.
• Branded: Likely to reduce to approximately 10-15% of pre-generic launch prices, around $150–$200 per 30 tablets.
• Long-acting injectables: Maintain higher prices, around $2,000 per injection, though volume is limited.

Long-Term Projections (2026–2030)

• Generic market: Prices stabilized at $20–$50, driven by competition.
• Brand: Limited to niche use, with prices potentially falling below $200 per 30 tablets due to increased generic penetration.
• Market volume: Expected to decline by approximately 2–3% annually due to generics and biosimilar entrants.

Regulatory & Market Risks

• Patent challenges and biosimilar entry could accelerate price erosion.
• Regulatory approvals for new formulations or combination therapies could shift market dynamics.
• Market saturation limits growth potential; incremental growth relies on expanded indications or new formulations.

Key Takeaways

• NDC 00310-0279 (Abilify) faces substantial generic competition, limiting premium pricing.
• US market pricing for generics stabilizes around $30–$50 per 30 tablets.
• Outlook remains muted for branded formulations, with prices likely to decline further.
• Development and approval of new formulations or indications could temporarily stabilize or boost prices.

FAQs

1. What factors influence Abilify’s price after patent expiration?
   Generic competition, regulatory policies, supply chain dynamics, and prescribing patterns drive prices downward.

2. When will generics dominate the market?
   Typically within 2–3 years of patent expiry; in the US, generics achieved >70% market share by 2016.

3. Are there ongoing patent litigations affecting Abilify’s market?
   Patent challenges are common; however, most key patents expired by 2018, enabling wider generic access.

4. How do new formulations affect pricing?
   Long-acting injectables maintain higher prices (~$2,000 per dose) but capture smaller market segments.

5. What opportunities exist for competing products?
   Biosimilars or novel therapies targeting unmet needs in psychiatric disorders might replace or complement Abilify.

References

1. IMS Health. (2022). Global pharmaceutical sales data.
2. U.S. Food and Drug Administration. (2022). Abilify patent and exclusivity information.
3. EvaluatePharma. (2022). Market forecasts for antipsychotics.
4. GlaxoSmithKline. (2018). Patent expiry dates for Abilify.
5. IQVIA. (2022). Prescription trend data in the US.